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Abstract: Galactomannan (GM) is widely used for detection of invasive aspergillosis in 
high-risk haemato-oncology patients. Recent publications have reported a lack of 
repeatability of GM detection. The objective of this retrospective study was to assess the 
repeatability of GM levels during storage of clinical samples. In a GM screening strategy, 
positive sera were repeat tested as per manufacturer’s recommendations. Short-term (ST) 
storage of samples was at +4 °C while long-term (LT) storage was at −80 °C. 
Bronchoalveolar (BAL) fluid was also repeating tested after ST storage and LT storage. 
Wilcoxon Signed Ranks Test was employed to assess the repeatability of GM levels. In a 
subset of 14 GM positive sera, repeat testing was performed on both the original serum and 
ethylenediaminetetraacetic acid (EDTA) pre-treated sample. There was a significant 
reduction in GM signals on repeat testing following ST storage (median GM index:  
0.65 vs. 0.19; p < 0.001) and LT storage (median GM index: 0.56 vs. 0.10; p < 0.001) of 
serum samples. Of samples that were initially GM positive, an average GM index 
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reduction of 50% was seen, with approximately two-thirds becoming GM negative on 
repeat testing of the same sample. In contrast, GM signal loss was not seen on repeat 
testing of BAL fluid following ST or LT storage. When GM positive serum samples were 
repeat tested using EDTA pre-treated serum from the first step of the testing protocol, all 
samples remained GM positive. In contrast, when the same samples were repeat tested 
from the original collected serum, 9 samples (64%) became GM negative. The significant 
reduction in GM signals during ST and LT storage of serum samples has implications for 
clinical management. Although the reasons for GM decline are unknown, they occur prior 
to the EDTA pre-treatment stage, indicating that the time from phlebotomy to testing 
should be minimized. BAL fluid GM index values remain stable. 
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1. Introduction 
Invasive pulmonary aspergillosis (IA) remains a life-threatening opportunistic invasive mycosis in 
immunocompromised patients [1]. The Platelia Aspergillus enzyme immunoassay (PA-EIA, Bio Rad, 
Marnes-la-Coquette, France) provides non-invasive, quantitative Aspergillus-specific detection and is 
widely used to detect serum galactomannan (GM) [2]. There is little information on the repeatability of 
GM Index results on repeat testing of the same sample after a period of sample storage. One study 
retrospectively evaluated GM concentrations in stored serum after a period of four years, reporting a 
lower reactivity in 20% of samples on retesting [3]. However, analysis of “real-time” results has also 
demonstrated significant between-run variability when testing is repeated on the same sample [4], 
underlying the importance of corroborating a positive result by retesting of the same sample. Two 
recently published articles have reported a lack of intra-laboratory repeatability with the PA-EIA test 
for GM detection. Oren et al. report a lack of repeatability when GM positive samples are retested 
within six days [5], with lower values in 29/34 (85%) repeats. Bizzini et al. [6] report a similar 
reduction in reactivity of samples on retesting of positive samples within three days, with lower values 
in 23/29 (79%) repeats. These observations raise doubts about the interpretation of data from 
frozen/thawed samples, as well as samples tested in “real-time” for patient management. The aim of 
this retrospective study was to clarify the effects of sample storage on the repeatability of GM levels 
using the PA-EIA.  
2. Results and Discussion 
2.1. Sample Results (Scatter Plot)  
Figure 1 shows that there was a clear loss of GM signal in both the short-term (ST) and long-term 
(LT) serum, with the signal loss more apparent in the plot including only the first sample taken from 
each patient (Figure 1A) than in the plot including all serum data (Figure 1B). Repeated samples from 
the same patient may mask the loss of signal in both ST and LT stored sera. Loss of GM signal was 
higher in LT than ST stored samples. BAL fluid samples did not show GM signal loss following either 
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in ST or LT storage (Figure 1C). Note that the removal of the two outlier values from Figure 1A,C 
does not change the shape of the relationships significantly. 
Figure 1. Scatter plot with fractional polynomial lines for reduction in Galactomannan 
(GM) level. Diagonal solid lines indicate the line of equality. (A) GM serum level 
excluding repeat sera from patients with multiple samples; (B) GM serum level including 
multiple samples from the same patient; (C) GM Bronchoalveolar (BAL) level  
(no repetition) during short-term and long-term storage. 
2.1.1. Hypothesis Testing  
Serum samples (without repetition): The Wilcoxon Signed Rank Sum Test applied to the first 
sample from each patient, showed statistically significant reductions in GM signals both in the ST 
storage (n = 65, median GM1 index: 0.65, median GM2 index: 0.19; p < 0.001) and in the LT storage 
Int. J. Mol. Sci. 2013, 14 12973 
 
 
(n = 35, median GM1 index: 0.56, median GM2 index: 0.10; p < 0.001), as shown in Table 1. In total, 
44/65 (68%) ST and 31/35 (89%) LT serum samples showed a reduction in GM signal upon  
repeat testing.  
In the ST serum group, 65.2% of samples that were initially GM positive became GM negative on 
repeat testing; with an average GM signal reduction of 50.2% in samples that were initially GM 
positive. In the LT serum storage group, 67.9% of GM positive samples became GM negative on 
repeat testing; with an average GM signal reduction of 49.3%.  
To ascertain the stage at which GM signal loss occurred, repeat testing in a subset of GM positive 
samples (n = 14) was performed following ST storage from the original serum sample or using the 
EDTA pre-treated sample. All EDTA pre-treated samples remained positive. In contrast 9/14 (64%) of 
repeats from the original serum sample became negative. 
Table 1. Results of the Wilcoxon Signed Rank Sum Test. 
 Sample size Samples with GM reduction Median GM1 index Median GM2 index p-value 
Short-Term Serum 65 44 0.65 0.19 <0.001 
Long-Term Serum 35 31 0.56 0.10 <0.001 
2.1.2. Assay Repeatability  
The repeatability of the OD of the threshold control run in duplicate over 40 randomly selected 
assays is shown in Figure 2. The duplicate values of the OD were repeatable as most of them are close 
to the line of equality and all measurements were within the recommended limits (OD 0.3–0.8). The 
mean OD of the 40 threshold control measurements was 0.49, with range 0.33–0.69. The coefficient of 
variation for duplicate measures was 7.09, which confirms repeatability.  
Figure 2. Scatter plot for repeatability of the threshold control: Controls provided with the 
Platelia Aspergillus enzyme immunoassay (PA-EIA) kit were loaded in duplicate wells 
(GM Index 1 and GM Index 2) over 40 randomly selected assay runs. Diagonal solid line 
indicates the line of equality. 
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2.2. Discussion 
The international EORTC/MSG (European Organization for Research and Treatment of 
Cancer/Invasive Fungal Infections Cooperation Group and the National Institute of Allergy and 
Infectious Diseases Mycoses Study Group) mycological criteria for diagnosing IA [7] include serum 
and BAL fluid GM results as key diagnostic criteria. These are routinely obtained using the PA-EIA, 
which provides non-invasive, quantitative Aspergillus-specific detection for serum GM. Recent reports 
have raised concerns with regard to the repeatability of GM levels. This report confirms these doubts 
and broadens these findings by establishing a lack of repeatability of serum GM testing of the same 
sample. A clinically significant reduction in GM reactivity was recorded, with two thirds of GM 
positive sera becoming negative following ST or LT storage. This phenomenon was not seen with 
repeat GM testing of BAL fluid following ST or LT storage. We have published our rate of invasive 
fungal disease (IFD) using the EORTC/MSG criteria of probable/proven IFD, which are usually 
regarded as representing true cases, as only 8/589 episodes (1.4%) by 2008 and 20/589 (3.5%) by 2002 
criteria [8]. It has been previously reported by Furfaro et al. [9] that the decrease in GM values after 
retesting was much more pronounced in those samples with initially false positive GM results. Clearly, 
in our practice, the phenomenon of GM signal loss cannot be correlated to the EORTC/MSG criteria of 
IFD given the much higher frequency GM signal loss in both ST and LT data sets. 
The OD value of the threshold control is critical in the calculation of the GM index value of clinical 
samples. Repeatability of the OD of the threshold control was confirmed by the CV for duplicate 
measures. These data indicate that technical issues per se cannot explain the observed GM signal loss 
in clinical samples. Furthermore, extensive review of the technical performance of the assay by 
different operators was undertaken, in conjunction with Bio-Rad, including monitoring of heating 
block temperature and plate washer performance. No concerns were identified. Although environmental 
contamination is a risk during testing, our data are not consistent with contamination, which would 
lead to random increases or decreases with repeat testing. In contrast, the presented data show a 
consistent pattern of signal loss, with the first reading being higher than the repeat. In addition, 
sporadic repeat testing of GM negative serum samples never gave a positive result. 
The repeatability of the OD of the threshold control suggests that the observed GM signal loss was 
specific to clinical serum samples. Interestingly, following ST storage of sera, the GM signal loss was 
not seen if the repeat was performed using EDTA pre-treated samples from the first step of the testing 
protocol, all of which remained positive. Although the mechanisms of GM decline in clinical serum 
samples are unclear, they appear to occur in the original serum sample prior to the EDTA  
pre-treatment stage. The data does not allow us to specify an acceptable storage time without major 
signal loss, but we can conclude that serum signal loss is associated with storage, and that it is 
therefore important to minimise the time from phlebotomy to the EDTA stage of processing. Further 
work needs to be done to determine whether short term storage without major signal loss is possible. 
The focus of our further investigations is on the stability of in vivo serum GM versus purified control 
GM, the impact of potential enzymatic epitope degradation/masking, as well as the correlation with 
any prescribed anti-microbial agents and other intravenous drugs. 
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3. Experimental Section  
3.1. Clinical Samples 
Serum and broncho-alveolar lavage (BAL) fluid samples were collected from patients in the 
Division of Haemato-Oncology at St Bartholomew’s Hospital undergoing serum GM monitoring in a 
screening strategy throughout their episode of intensive chemotherapy. Samples were sent, and GM 
detection was performed by PA-EIA, twice weekly. Techniques were carried out as recommended by 
the manufacturer. Results were expressed as a GM index value—The ratio of the sample optical 
density (OD) divided by the mean OD of the 2 threshold controls. Serum samples were scored as 
positive if the GM index was >0.5. In our institution, it is routine practice to confirm a positive result 
(GM1) by repeat testing (GM2) from the original sample, as recommended by the manufacturer. For 
GM negative serum samples, repeat testing was sporadically performed for performance analysis. 
Short-term (ST) storage at +4 °C: Microbiology laboratory records from February 2009 to March 
2010 were filtered to exclude GM data (i) for non-serum samples and (ii) samples repeat-tested after 
greater than 48hours. A total of 109 serum samples (from 65 different patients) and 8 BAL fluid 
samples were identified.  
Long-term (LT) storage at −80 °C: A total of 54 serum samples (from 35 different patients) and  
12 BAL fluid samples were collected from July 2005 to September 2007, GM tested and sample 
aliquots were stored at −80 °C. These samples were repeat tested after 2–4 years storage at −80 °C in 
2009. In total, 183 clinical samples were included in this study. 
3.2. Analysis of Clinical Data 
Data from serum testing are presented on a scatter plot, with fractional polynomial regression lines 
for each storage type. As the relationship between the two test results was found not to be linear, 
fractional polynomial regression was the best choice to capture the exact relationship between them. 
Due to routine twice-weekly screening of high-risk patients, more than one sample was collected for 
most of the patients. As first and second test values are likely to be correlated, the Wilcoxon Signed 
Rank Sum Test was used to test the GM signal loss both in the ST as well as LT serum samples based 
on the first sample taken from each patient. Probability values <0.05 were defined as significant based 
on a 2-tailed test. All calculations were carried out using the statistical software package Intercooled 
STATA 10.1 (Stat Corp, College Station, TX, USA, 2008).  
3.3. Assay Repeatability 
In order to determine the intra- and inter-assay variability, the OD value of the threshold control, 
loaded in duplicate, was recorded for 40 randomly selected assay runs. The mean OD was calculated, 
together with range. Inter-assay repeatability of the threshold control was calculated by using the Jones 
and Payne [10] coefficient of variation (CV) for duplicate measures. 
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4. Conclusions  
These observations suggest that: (i) caution should be exercised when testing serum samples after a 
period of storage, including samples stored at −80 °C; (ii) the interpretation of GM negative results 
obtained after delays in processing may be problematic; (iii) careful coordination is required between 
the laboratory and clinical teams to minimise the time from sampling to testing; (iv) a better 
understanding of GM kinetics is necessary to address the impact of sample processing and storage 
times on detectable GM concentrations. Furthermore, given a wide range of sensitivity and specificity 
data plus multiple causes of false-positive results for the PA-EIA reported in the literature, a prudent 
approach to clinical utilization of GM testing would be to combine the PA-EIA with other markers of 
Aspergillus in a diagnostic algorithm [11,12]. 
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